Protective effects of saponin on a hypertension target organ in spontaneously hypertensive rats

The present study was undertaken to investigate the protective effects of saponin on a hypertensive target organ (the kidney) in spontaneously hypertensive rats (SHRs) and also to explore the effect of saponin on the renin-angiotensin-aldosterone system (RAAS). A total of 24, 14-week-old SHRs were randomly divided into three groups; the first was administered low-dose saponin, the second with high-dose saponin and the third with a placebo as the control group. An additional eight healthy male Wistar rats were used as the normal group. The blood pressures (BPs) of the rats were determined using an animal BP-6 non-invasive blood pressure tester. Furthermore, the gene expression of TGFB1, collagen I and prorenin receptor (PRR) was determined by quantitative real time (qRT)-PCR. The histopathological and morphological features of the tissue samples were assessed semi-quantitatively. The content of saponin in the renal samples was lower in SHRs than in the normal healthy rats, but the plasma levels of saponin were similar. Mean arterial pressure (MAP) was reduced 5 days subsequent to saponin treatment by 36±3 and 51±4 mmHg in the low- and high-dose saponin groups, respectively. The anti-hypertensive effect of saponin was dose-related during the first 4 weeks of treatment. The gene expression of TGFB1 and collagen I in the renal samples was significantly suppressed in the low- and high-dose saponin groups compared with that in the control group. The gene expression of PRR was significantly and dose-dependently increased in the saponin-treated groups. These findings suggested that saponin reduced systemic BP and blocked the circulating and tissue RAAS.

[1]  Rajesh Kumar,et al.  High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. , 2007, American journal of physiology. Heart and circulatory physiology.

[2]  A. Nishiyama,et al.  Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  R. Plehm,et al.  Elevated Blood Pressure and Heart Rate in Human Renin Receptor Transgenic Rats , 2006, Hypertension.

[4]  A. Nishiyama,et al.  Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. , 2004, The Journal of clinical investigation.

[5]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[6]  J. Bauersachs,et al.  Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. , 2003, Minerva cardioangiologica.

[7]  C. Delcayre,et al.  Molecular mechanisms of myocardial remodeling. The role of aldosterone. , 2002, Journal of molecular and cellular cardiology.

[8]  S. Katz,et al.  Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure , 2002, Circulation.

[9]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[10]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[11]  A. Ledbetter,et al.  The spontaneously hypertensive rat as a model of human cardiovascular disease: evidence of exacerbated cardiopulmonary injury and oxidative stress from inhaled emission particulate matter. , 2000, Toxicology and applied pharmacology.

[12]  Terje Sagvolden,et al.  Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD) , 2000, Neuroscience & Biobehavioral Reviews.

[13]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[14]  K. Weber,et al.  Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.

[15]  G Olivetti,et al.  Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. , 1990, Circulation research.

[16]  W. Border,et al.  Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. , 1998, Hypertension.

[17]  D. Ganten,et al.  Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. , 1996, Blood pressure. Supplement.